Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit.
about
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersA large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies.Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.Biosynthesis of a biologically active single peptide chain containing the human common alpha and chorionic gonadotropin beta subunits in tandem.Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors.Gonadotrophins: The future.A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity.Structure-function relationships of glycoprotein hormones and their subunits' ancestors.The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist.Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-control study.Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysisHistorical perspectives in gonadotrophin therapy.Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulationSecretory trafficking signal encoded in the carboxyl-terminal region of the CGbeta-subunit.Efficacy of native and hyperglycosylated follicle-stimulating hormone analogs for promoting fertility in female mice.Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patientsAdvances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency.The mammalian ovary from genesis to revelation.MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults.Trends in recombinant protein use in animal production.Corifollitropin alfa: a novel long-acting recombinant follicle-stimulating hormone agonist for controlled ovarian stimulation.Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction.Corifollitropin alfa for female infertility.Designing a Long Acting Erythropoietin by Fusing Three Carboxyl-Terminal Peptides of Human Chorionic Gonadotropin β Subunit to the N-Terminal and C-Terminal Coding Sequence.Use of protein knobs to characterize the position of conserved alpha-subunit regions in lutropin receptor complexes.Expression of biologically active fusion genes encoding the common alpha subunit and the follicle-stimulating hormone beta subunit. Role of a linker sequence.Production of biologically active recombinant goose FSH in a single chain form with a CTP linker sequence.Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications.Receptor specificity and functional comparison of recombinant sea bass (Dicentrarchus labrax) gonadotropins (FSH and LH) produced in different host systems.The recombinant equine LHβ subunit combines divergent intracellular traits of human LHβ and CGβ subunits.The LHbeta gene of several mammals embeds a carboxyl-terminal peptide-like sequence revealing a critical role for mucin oligosaccharides in the evolution of lutropin to chorionic gonadotropin in the animal phyla.Engineering a potential antagonist of human thyrotropin and thyroid-stimulating antibody.Strategies to Develop Therapeutic N- and O-Hyperglycosylated Proteins.Selective use of corifollitropin for controlled ovarian stimulation for IVF in patients with low anti-Müllerian hormone.Development and characterization of a novel long-acting recombinant follicle stimulating hormone agonist by fusing Fc to an FSH-β subunit.Administration of corifollitropin alfa on Day 2 versus Day 4 of the cycle in a GnRH antagonist protocol: a randomized controlled pilot study.Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation.A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation.Pharmacokinetics, Pharmacodynamics, and Safety of a Long-Acting Human Growth Hormone (MOD-4023) in Healthy Japanese and Caucasian Adults.
P2860
Q26801319-96B9BB44-2CCB-4A21-AF3C-0CE7A4EE6B16Q30717070-AA874C47-5034-4293-8B5B-A3FEA0AC659DQ30796722-DEA9A9B8-9167-4057-80EA-C177D40E4C6FQ34563270-440DC5F9-DC38-4F6E-8B5D-D1165D3F6FCAQ34607225-6098AC74-9EF0-4FC8-B793-AB2453079C95Q34975528-49CE7DF2-CD15-4418-8FD2-351776324F47Q34997672-DFDBBF7F-9DC3-4E51-BC1F-36A444840347Q35108282-ADF470EB-02DF-48A8-84F8-3C454D8670EDQ35124421-68419376-68A1-4883-8BC7-7E69920C497AQ35186161-337EF5F0-A96D-4B83-9049-AC3AA5DCF0D3Q35186866-569BB08D-3CF8-48A5-BD3B-50FE69F3E6B3Q35735337-F8658FED-C02C-40FF-91F1-ACE5484BA6E0Q35896964-4864CD1F-8DFF-4950-9356-99230BB390ECQ37030672-979F60B1-30D9-478E-90DD-A80209A5052AQ37125459-B132A536-B3E6-4523-B976-E76373BEDE32Q37357158-45E036CC-906B-4C20-AEBD-9989C6148B43Q37358128-7314051C-FD85-4BF5-9938-949BEEBC4E66Q37381361-3DA29F8F-646D-4E37-AF1A-27ED1C204E7BQ37385514-36BC5D8B-636F-45FD-ACEE-F0E8221C6922Q37626107-8D898113-9EF6-4E63-95E7-6C7DF753D653Q37680197-C61F9D6E-A208-44FF-81B5-3BDF67473B54Q37795798-858BA0E1-666A-408A-AB99-2AC70AC17935Q37911498-E673B3F1-8A35-40B4-919C-D2AE0763356FQ37962998-1FDAF9D7-1BD6-4F89-896D-2B3DD3FC1346Q38253856-C43E52A8-662A-4810-89AD-7BD91E7C975FQ38337907-2AA998BF-FEA5-4C8C-AA16-8FC36DAFC0BFQ38358040-3749BD7D-9E7C-4536-B33F-D68A70EC5772Q38727937-DE397F09-CB2D-4F46-A461-0631727BFDB2Q39149359-DB8141A7-F86F-4519-8089-FA9F2F2B8DE7Q39598033-730CF39A-E5CC-42B2-AA43-8021AA539137Q41183946-2D60CAD8-C6E7-41CC-93C6-9163848950E9Q42648502-FE8538CF-B33F-4F29-9566-AF667384F1D4Q43510073-A93107D7-BA5A-4602-B267-2D0B8D115310Q47786864-BC2EFD7B-3E6E-4773-9018-23C507B09565Q48557184-B1C80F46-4DAE-41B7-BEC9-C2DF4FBCF3F0Q48563210-229A2A34-6324-4FA9-A36E-B5D53FCCA705Q48602680-86798A29-1A20-4C3B-90EF-2DD8597205BDQ48697489-0ECC2A7F-16EA-4052-BE8C-577057DB1765Q48742001-7290983C-6090-404B-98BA-3D2CA990241FQ50026005-C02AF877-DA0B-4407-8BCB-E670181F487F
P2860
Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 1992
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Design of a long-acting follit ...... the follitropin beta subunit.
@en
Design of a long-acting follit ...... the follitropin beta subunit.
@nl
type
label
Design of a long-acting follit ...... the follitropin beta subunit.
@en
Design of a long-acting follit ...... the follitropin beta subunit.
@nl
prefLabel
Design of a long-acting follit ...... the follitropin beta subunit.
@en
Design of a long-acting follit ...... the follitropin beta subunit.
@nl
P2093
P2860
P356
P1476
Design of a long-acting follit ...... the follitropin beta subunit.
@en
P2093
P2860
P304
P356
10.1073/PNAS.89.10.4304
P407
P577
1992-05-01T00:00:00Z